Heidelberg Pharma AG (XTER:HPHA) Total Current Assets: €37.83 Mil (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:HPHA Heidelberg Pharma AG XTER:HPHA
52 GF Score
Price €2.55
GF Value €2.87
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Heidelberg Pharma AG Total Current Assets?

Heidelberg Pharma AG XTER:HPHA -1.92% 52 Total Current Assets is €37.83 Mil as of May. 2026. GuruFocus rates XTER:HPHA with a GF Score™ of 52/100 and a GF Value™ of €2.87 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Heidelberg Pharma AG's total current assets for the quarter that ended in May. 2026 was €37.83 Mil.

Heidelberg Pharma AG  (XTER:HPHA) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Heidelberg Pharma AG's Liquidation Value for the quarter that ended in May. 2026 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=24.93-61.115+0.75 * 0.128+0.5 * 10.41
=-30.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Heidelberg Pharma AG Total Current Assets Related Terms

Heidelberg Pharma AG Total Current Assets Historical Data

* Premium members only.

The historical data trend for Heidelberg Pharma AG's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Heidelberg Pharma AG Total Current Assets Chart

Heidelberg Pharma AG Annual Data
Trend Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23 Nov24 Nov25
Total Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.01 87.88 56.63 47.57 28.33

Heidelberg Pharma AG Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 49.21 40.95 28.33 21.63 37.83
XTER:HPHA
52GF Score
Heidelberg Pharma AG XTER:HPHA
Total Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Heidelberg Pharma AG Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Heidelberg Pharma AG's Total Current Assets for the fiscal year that ended in Nov. 2025 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=14.976+0.795+9.164+3.395
=28.33

Heidelberg Pharma AG's Total Current Assets for the quarter that ended in May. 2026 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=24.93+2.146+10.41+0.34699999999999
=37.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Frequently Asked Questions Learn more about Total Current Assets →
What does a Total Current Assets of €37.83 Mil mean?
Heidelberg Pharma AG (XTER:HPHA) has a Total Current Assets of €37.83 Mil as of May. 2026. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Heidelberg Pharma AG and its competitors.
Is Heidelberg Pharma AG's Total Current Assets too high?
Heidelberg Pharma AG's current Total Current Assets is €37.83 Mil. Overall, Heidelberg Pharma AG has a GF Score™ of 52/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Heidelberg Pharma AG's Total Current Assets compare to VRTX and REGN?
Heidelberg Pharma AG's Total Current Assets of €37.83 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Biotechnology company?
A good Total Current Assets depends on the Biotechnology industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Heidelberg Pharma AG and its competitors. Heidelberg Pharma AG's current Total Current Assets is €37.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Heidelberg Pharma AG stock overvalued right now?
Based on GuruFocus' analysis, Heidelberg Pharma AG (XTER:HPHA) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.87, compared to a current price of €2.55 — trading 11.1% below its estimated fair value. The current Total Current Assets is €37.83 Mil. Heidelberg Pharma AG's overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For Heidelberg Pharma AG (XTER:HPHA), the current Total Current Assets is €37.83 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Heidelberg Pharma AG (XTER:HPHA) Overvalued in 2026?

Based on GuruFocus' analysis, Heidelberg Pharma AG stock appears to be undervalued. The current stock price of €2.55 is trading 11.1% below its estimated GF Value™ of €2.87. GuruFocus considers Heidelberg Pharma AG to be Modestly Undervalued.

Key valuation signals for XTER:HPHA:

  • Total Current Assets: €37.83 Mil
  • GF Value™: €2.87 vs. price of €2.55 (11.1% below fair value)
  • GF Score™: 52/100 with 5 warning signs

No single metric tells the full story. See the XTER:HPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Heidelberg Pharma AG Business Description

Other Exchanges 0QW5:UKHPHA:Austria
Address Gregor-Mendel-Street 22, Ladenburg, DEU, 68526
Heidelberg Pharma AG is a biopharmaceutical company developing oncology treatments through antibody drug conjugates (ADCs), which combine antibody specificity with toxin potency to selectively target and kill cancer cells. The Company researches, develops, and produces these ADCs, and has built an ADC toolbox using various antibodies and payloads to address multiple cancers and overcome tumor resistance. Its activities focus on its proprietary ATAC technology based on Amanitin, the toxin of the death cap mushroom, leveraging its biological mechanism as a novel cancer therapy. The ATAC platform is used to develop proprietary ADC candidates and is also applied in collaborations with third parties.
52GF Score

Get the complete analysis for XTER:HPHA

Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.55
Price
€2.87
GF Value